Wacker Biotech is “THE MICROBIAL CDMO” – the partner of choice for process transfer and/or development and commercial manufacturing of biopharmaceuticals (proteins, vaccines and live microbial products) using microbial hosts. Wacker Biotech has progressive experience producing vaccines, extending from classic inactivated and live attenuated vaccines to protein-based, polysaccharide and glycoconjugate vaccines.
WACKER’s integrated service portfolio covers molecular biology, process- and analytical development as well as GMP manufacturing of biologics for (pre)clinical and commercial supply. WACKER’s outstanding E. coli technologies can significantly increase the bioprocess efficiency and thereby reduce the cost of goods. We produce with manufacturing lines with a capacity of up to 1,500L to flexibly serve our clients, ranging from small biotechnology companies to big pharmaceutical corporates.